2022
A multi-pronged investigation of option generation using depression, PET and modafinil
Ang Y, Cusin C, Petibon Y, Dillon D, Breiger M, Belleau E, Normandin M, Schroder H, Boyden S, Hayden E, Levine M, Jahan A, Meyer A, Kang M, Brunner D, Gelda S, Hooker J, Fakhri G, Fava M, Pizzagalli D. A multi-pronged investigation of option generation using depression, PET and modafinil. Brain 2022, 145: 1854-1865. PMID: 35150243, PMCID: PMC9166534, DOI: 10.1093/brain/awab429.Peer-Reviewed Original ResearchConceptsD2/D3 receptor availabilitySelf-generated optionsDepressive disorderDepressed individualsReceptor availabilityDopamine D2/D3 receptor availabilityNon-depressed adultsEffects of modafinilPutamen of patientsAssociated with uniquenessOption generationD2/D3 receptorsDopaminergic activityClinical depressionBinding potentialModafinilHealthy participantsPutamenPlacebo-controlledSamples of healthy peopleDouble-blindDisordersSelf-generationHealthy controlsDopamine
2021
In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker
Mody M, Petibon Y, Han P, Kuruppu D, Ma C, Yokell D, Neelamegam R, Normandin M, Fakhri G, Brownell A. In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker. Scientific Reports 2021, 11: 15897. PMID: 34354107, PMCID: PMC8342610, DOI: 10.1038/s41598-021-94967-y.Peer-Reviewed Original ResearchConceptsFragile X syndromeFragile X mental retardation proteinX syndromeLoss of fragile X mental retardation proteinMGlu5 receptor expressionMetabotropic glutamate subtype 5 receptorsDrug occupancy studiesSignificant group differencesFragile X mental retardationHealthy controlsAnterior cingulateMGluR5 availabilityVisuospatial processingMGlu5 receptorsOlfactory cortexBrain areasGroup differencesRetardation proteinGlutamate signalingImages of maleNeurodevelopmental disordersExcessive glutamate signalingGender-matched controlsDisordersMGluR5Speech intelligibility loss due to amyotrophic lateral sclerosis: the effect of tongue movement reduction on vowel and consonant acoustic features
Rong P, Usler E, Rowe L, Allison K, Woo J, Fakhri G, Green J. Speech intelligibility loss due to amyotrophic lateral sclerosis: the effect of tongue movement reduction on vowel and consonant acoustic features. Clinical Linguistics & Phonetics 2021, 35: 1091-1112. PMID: 33427505, DOI: 10.1080/02699206.2020.1868021.Peer-Reviewed Original ResearchConceptsTarget wordsIntelligence declineSpeech intelligibilityPredictors of speech intelligibilityDysarthria secondary to amyotrophic lateral sclerosisMotor performanceHealthy controlsReduced speech intelligibilityAcoustic featuresPhonetic distinctionsSpeech soundsRobust predictorsTongue movementDisease-related changesSpeech intelligibility declinesAmyotrophic lateral sclerosisTongue dynamicsMeasurement typesReduced rangeImpaired tongue movementMovement reductionWordsTongue bladeVowelsSpeech
2019
Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder
Pizzagalli D, Berretta S, Wooten D, Goer F, Pilobello K, Kumar P, Murray L, Beltzer M, Boyer-Boiteau A, Alpert N, Fakhri G, Mechawar N, Vitaliano G, Turecki G, Normandin M. Assessment of Striatal Dopamine Transporter Binding in Individuals With Major Depressive Disorder. JAMA Psychiatry 2019, 76: 854-861. PMID: 31042280, PMCID: PMC6495358, DOI: 10.1001/jamapsychiatry.2019.0801.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDA transporter availabilityVentral tegmental areaDA transporterDAT availabilityTegmental areaDepressive disorderDA signalingPositron emission tomographyDAT expressionMcLean HospitalHealthy controlsMajor depressive disorder groupsNumbers of depressive episodesStriatal dopamine transporter bindingDA transporter levelsLevels of DAT expressionStriatal DAT expressionStriatal DAT availabilityDA transporter densityDAT binding potentialDopamine transporter bindingOlder healthy controlsMesolimbic pathwayDA clearanceEvaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects
Guehl N, Wooten D, Yokell D, Moon S, Dhaynaut M, Katz S, Moody K, Gharagouzloo C, Kas A, Johnson K, El Fakhri G, Normandin M. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2099-2111. PMID: 31332496, PMCID: PMC6709592, DOI: 10.1007/s00259-019-04419-z.Peer-Reviewed Original ResearchConceptsReference tissue methodDistribution volume ratioTissue methodIn vivo quantificationPharmacokinetic modeling strategiesArterial plasma input functionMultilinear reference tissue methodsTwo-tissue compartment modelBlood:plasma ratioTissue-to-plasmaPlasma input functionPlasma concentration time courseBlood-based methodMethodsThirty-five subjectsSUV ratioBlood-based analysesData setsArterial input functionPET scansControl subjectsMild cognitive impairmentPlasma ratioRadiometabolite analysisHealthy controlsConcentration time course